The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction

Abstract

Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.

Keywords

atorvastatin erectile dysfunction quinapril

References

Maas R , Schwedhelm E , Albsmeier J , Boger RH . The patho-physiology of erectile dysfunction related to endothelial dys-function and mediators of vascular function. Vasc Med 2002; 7: 213–225.

Fung MM , Bettencourt R , Barrett-Connor E . Heart disease risk factors predict erectile dysfunction 25 years later. J Am Coll Cardiol 2004; 43: 1405–1411.

Billups KL , Kaiser DR , Kelly AS et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003; 15: 231–236.

Kaiser DR , Billups K , Mason C , Wetterling R , Lundberg JL , Bank AJ . Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179–184.

Bocchio M , Desideri G , Scarpelli P et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 2004; 171: 1601–1604.

Esposito K , Guigliano F , Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men, a randomized controlled trial. J Am Med Assoc 2004; 291: 2978–2984.

Guay AT . Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl 2003; 24: S59–S62.

McCullough AR , Barada JH , Fawzy A , Guay AT , Hatzichristou D . Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60: S28–S38.

Jarvisalo MJ , Toikka JO , Vasankari T et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999; 147: 237–342.

10.

Mancini GB , Henry GC , Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery dis-ease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258–265.

11.

Knoll LD , Abrams JH . Evaluation of penile ultrasonic velocitometry versus penile duplex ultrasonography to assess penile arterial hemodynamics. Urology 1998; 51: 89–93.

12.

Rosen RC , Cappelleri JC , Smith MD , Lipsky J , Pena BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.

13.

Cappelleri JC , Rosen RC , Smith MD , Mishra A , Osterloh IH . Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346–351.

14.

Kelly AS , Kaiser DR , Dengel DR , Bank AJ . Comparison of B-mode and echo-tracking methods of assessing flow-mediated dilation. Ultrasound Med Biol 2004; 30: 1447–1449.

15.

Billups KL , Bank AJ , Padma-Nathan H , Katz S , Williams R . Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med 2005; 2: 40–52.

16.

Ascer E , Bertolami MC , Venturinelli ML et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004; 177: 161–166.

17.

Haendeler J , Hoffmann J , Zeiher AM , Dimmeler S . Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004; 110: 856–861.

18.

Khan BV , Sola S , Lauten WB et al. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004; 27: 1712–1715.

19.

Fogari R , Zoppi A , Poletti L , Marasi G , Mugellini A , Corradi L . Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31.

20.

Caro JLL , Vidal JVL , Vicente JA et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.

21.

Saltzman EA , Guay AT , Jacobson J . Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255–258.